NCT07316621

Brief Summary

The PREDICT-CD study aims to validate a risk score for the development of Crohn's disease, based on serological biomarkers and lifestyle-related factors. Given that having a family member with the disease is the strongest known risk factor, the target population will consist of first-degree relatives (aged 16 to 35) of individuals diagnosed with Crohn's disease. This study will be conducted within Work Package 3 (WP3) of the INTERCEPT project, a consortium funded by the Innovative Health Initiative (IHI). The research will take place across 28 centres in seven countries: Portugal, Spain, France, Italy, the Netherlands, Sweden, and Poland. To achieve the study objectives, individuals with Crohn's disease (referred to as patients) will be invited to participate and to engage their eligible first-degree relatives. At the baseline visit, the patient's physician will complete a clinical questionnaire covering disease history, treatments, and previous interventions. At the same time, first-degree relatives (parents, siblings, or children) will donate a blood sample for serum isolation and, optionally, a whole blood and stool sample. They will also complete a questionnaire regarding their health status, habits, and preferences. Follow-up questionnaires will be administered every six months to monitor the onset of symptoms or behavioural changes.

Trial Health

83
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
42mo left

Started Apr 2026

Typical duration for all trials

Geographic Reach
6 countries

10 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Apr 2026Dec 2029

First Submitted

Initial submission to the registry

December 5, 2025

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 5, 2026

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

July 29, 2026

Status Verified

July 1, 2026

Enrollment Period

3.8 years

First QC Date

December 5, 2025

Last Update Submit

July 27, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Development of Crohn's disease during the study period

    Diagnosis confirmed according to established diagnostic criteria, specifically endoscopy and histopathology

    From enrolment until end of study follow-up (up to 3 years)

Secondary Outcomes (4)

  • Proportion of first-degree relatives classified as high risk according to the PREDICT-CD risk prediction algorithm

    From enrolment until end of study follow-up (up to 3 years)

  • Clinical and lifestyle characteristics of high-risk individuals who develop inflammatory bowel disease

    From enrolment until end of study follow-up (up to 3 years)

  • Incidence of newly diagnosed immune-mediated inflammatory diseases other than Crohn's disease

    From enrolment until end of study follow-up (up to 3 years)

  • Participant-reported willingness to receive predictive risk information and participate in preventive interventions

    From enrolment until end of study follow-up (up to 3 years)

Study Arms (1)

First-degree relatives

Eligibility Criteria

Age16 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodProbability Sample
Study Population

The first-degree relative without a previous diagnosis of Inflammatory Bowel Disease

You may qualify if:

  • Male or female participants, between 16 and 35 years old
  • FDR (parent, full-siblings or offspring) from a patient with an established diagnosis of CD
  • Participants able to understand the information provided to them and to give written informed assent or consent for the study.

You may not qualify if:

  • Prior diagnosis of IBD
  • Any legal or medical condition that limits the information and participation in the study
  • Inability to verify CD diagnosis in the proband
  • Participants unwilling or unable to provide informed written consent
  • Participants unwilling or unable to donate blood for serum

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Roma, Italy

RECRUITING

AUMC

Amsterdam, Netherlands

RECRUITING

UMCG

Groningen, Netherlands

RECRUITING

Państwowy Instytut Medyczny MSWiA w Warszawie

Warsaw, Poland

RECRUITING

Hospital Beatriz Ângelo

Lisbon, Portugal

RECRUITING

Hospital da Luz Lisboa

Lisbon, Portugal

RECRUITING

Hospital dos Capuchos

Lisbon, Portugal

RECRUITING

Hospital Santa Maria

Lisbon, Portugal

RECRUITING

Hospital Galdakao-Usansolo

Galdakao, Spain

RECRUITING

Örebro University Hospital

Örebro, Sweden

RECRUITING

MeSH Terms

Conditions

Crohn Disease

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 5, 2025

First Posted

January 5, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2029

Last Updated

July 29, 2026

Record last verified: 2026-07

Data Sharing

IPD Sharing
Will not share

Locations